First signal-finding study of soluble HLA-G and -E (sHLA-G/E) as potential prognostic markers of clinical outcome in advanced, refractory squamous-cell NSCLC (SCC) treated with nivolumab (NIVO) : checkMate 063

MLA

Eberhardt, Wilfried, et al. First Signal-Finding Study of Soluble HLA-G and -E (SHLA-G/E) as Potential Prognostic Markers of Clinical Outcome in Advanced, Refractory Squamous-Cell NSCLC (SCC) Treated with Nivolumab (NIVO) : CheckMate 063. Jan. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.unidue...bib..efc71f4dd1077f5262b3391b8563786f&authtype=sso&custid=ns315887.

APA

Eberhardt, W., Rebmann, V., Rizvi, N., Antonia, S. J., Planchard, D., Cappuzzo, F., Mazieres, J., Zalcman, G., Lena, H., Wolf, J., Horn, L., Stinchcombe, T., Dy, G., Blackwood-Chirchir, A., Jin, C., Geese, W. J., & Ramalingam, S. S. (2017). First signal-finding study of soluble HLA-G and -E (sHLA-G/E) as potential prognostic markers of clinical outcome in advanced, refractory squamous-cell NSCLC (SCC) treated with nivolumab (NIVO) : checkMate 063.

Chicago

Eberhardt, Wilfried, Vera Rebmann, N. Rizvi, S. J. Antonia, D. Planchard, F. Cappuzzo, J. Mazieres, et al. 2017. “First Signal-Finding Study of Soluble HLA-G and -E (SHLA-G/E) as Potential Prognostic Markers of Clinical Outcome in Advanced, Refractory Squamous-Cell NSCLC (SCC) Treated with Nivolumab (NIVO) : CheckMate 063,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.unidue...bib..efc71f4dd1077f5262b3391b8563786f&authtype=sso&custid=ns315887.